AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma Ltd	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	202239	ANDA	AvKARE	42291-011-01	100 CAPSULE in 1 BOTTLE (42291-011-01)	2023-06-20
Aurobindo Pharma Ltd	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	202239	ANDA	AvKARE	42291-014-01	100 CAPSULE in 1 BOTTLE (42291-014-01)	2023-06-20
Aurobindo Pharma Ltd	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	202239	ANDA	AvKARE	42291-015-01	100 CAPSULE in 1 BOTTLE (42291-015-01)	2023-06-20
Aurobindo Pharma Ltd	AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE	amlodipine besylate; benazepril hydrochloride	CAPSULE;ORAL	202239	ANDA	A-S Medication Solutions	50090-1042-0	30 CAPSULE in 1 BOTTLE (50090-1042-0)	2012-09-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Amlodipine Besylate and Benazepril Hydrochloride are widely prescribed medications for hypertension and cardiovascular conditions. The supply chain for these active pharmaceutical ingredients (APIs) involves a global network of chemical manufacturers, intermediates suppliers, and formulators. Key suppliers are concentrated in Asia, with India and China leading production. The patent landscape for both drugs has largely expired, leading to a competitive generic market. This analysis identifies major API suppliers, examines regulatory considerations, and assesses potential supply chain risks.

WHO ARE THE KEY API SUPPLIERS FOR AMLODIPINE BESYLATE?

Amlodipine Besylate is a dihydropyridine calcium channel blocker. Major suppliers of its API include companies with significant chemical synthesis capabilities.

Teva Pharmaceuticals: A global pharmaceutical giant with API manufacturing facilities, Teva is a significant producer of Amlodipine Besylate for its own formulations and for sale to other generic manufacturers.
Dr. Reddy's Laboratories: This Indian multinational pharmaceutical company is a prominent supplier of Amlodipine Besylate API. They possess robust manufacturing infrastructure and adhere to international quality standards.
Lupin Limited: Another major Indian pharmaceutical company, Lupin produces and supplies Amlodipine Besylate API, serving both domestic and international markets.
Sun Pharmaceutical Industries Ltd.: Sun Pharma, headquartered in India, is a leading global pharmaceutical company and a consistent supplier of Amlodipine Besylate API.
Anacor Pharmaceuticals (now part of Pfizer): While Anacor was acquired by Pfizer, its historical role in API development and manufacturing is relevant. Pfizer's extensive network likely includes production capabilities for Amlodipine Besylate.
Aarti Industries Limited: This Indian company is a significant manufacturer of specialty chemicals and pharmaceuticals, including APIs like Amlodipine Besylate.
Zhejiang NHU Company Ltd.: A Chinese chemical and pharmaceutical manufacturer, Zhejiang NHU is a substantial global supplier of APIs, including Amlodipine Besylate.
Jiangsu Yangnong Chemical Group Co., Ltd.: A large Chinese chemical enterprise that also produces pharmaceutical intermediates and APIs.

These suppliers operate under strict Good Manufacturing Practices (GMP) and are subject to audits by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The production process for Amlodipine Besylate API involves multi-step chemical synthesis starting from various precursors.

WHO ARE THE KEY API SUPPLIERS FOR BENAZEPRIL HYDROCHLORIDE?

Benazepril Hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor. The production of its API also requires sophisticated chemical synthesis.

Mylan N.V. (now part of Viatris): Mylan, before its merger into Viatris, was a major player in the generic pharmaceutical market and a significant producer of Benazepril Hydrochloride API. Viatris continues this role.
Aurobindo Pharma: An Indian multinational pharmaceutical company, Aurobindo is a substantial producer of APIs, including Benazepril Hydrochloride, for global markets.
Hetero Drugs Ltd.: Hetero is one of India's largest pharmaceutical companies and a major supplier of APIs, with Benazepril Hydrochloride being part of its portfolio.
Torrent Pharmaceuticals: This Indian company manufactures and markets a wide range of pharmaceutical products, including APIs like Benazepril Hydrochloride.
Cipla Limited: Cipla is a well-established Indian pharmaceutical company with significant API manufacturing capabilities, supplying Benazepril Hydrochloride globally.
Emmennar Drug Company: An Indian API manufacturer that produces Benazepril Hydrochloride.
Novartis AG: While primarily known for branded pharmaceuticals, Novartis has a significant generics division (Sandoz), and its broader manufacturing network likely includes production of key generic APIs like Benazepril Hydrochloride.
Shandong Xinhua Pharmaceutical Company Limited: A major Chinese pharmaceutical manufacturer with extensive API production, including Benazepril Hydrochloride.
Hisun Pharmaceutical Co., Ltd.: Another large Chinese pharmaceutical company involved in the research, development, manufacturing, and sale of APIs.

The synthesis of Benazepril Hydrochloride API involves complex chemical reactions, and consistent quality is paramount. Suppliers must comply with stringent regulatory requirements to ensure patient safety and drug efficacy.

WHAT IS THE PATENT LANDSCAPE FOR AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE?

Both Amlodipine Besylate and Benazepril Hydrochloride are off-patent drugs in major markets. This has facilitated the entry of numerous generic manufacturers, leading to price competition.

Amlodipine Besylate Patent Status:

Original Patent Expiration: The primary patents protecting Amlodipine Besylate, originally developed by Pfizer under the brand name Norvasc, expired decades ago. The U.S. patent for amlodipine expired in 2003.
Generic Market Dominance: The expiration of key patents allowed for the widespread introduction of generic versions. Today, the market is dominated by generic manufacturers, with numerous companies holding Abbreviated New Drug Applications (ANDAs) approved by the FDA.
Subsequent Patents: While the core compound patent has long expired, secondary patents related to specific formulations, polymorphs, or manufacturing processes may have existed or expired at different times. However, these have not prevented the robust generic market.

Benazepril Hydrochloride Patent Status:

Original Patent Expiration: Benazepril Hydrochloride was developed by Novartis and marketed as Lotensin. The patent protection for the original compound also expired many years ago.
Generic Market Entry: Similar to Amlodipine Besylate, the expiration of Benazepril Hydrochloride patents opened the door for generic competition. Multiple companies have secured FDA approval for their generic versions.
Process and Formulation Patents: As with amlodipine, patents related to specific manufacturing processes or novel formulations of benazepril hydrochloride may have been pursued. However, the expired composition-of-matter patents have allowed for broad generic availability.

The absence of patent exclusivity means that market share for these drugs is primarily determined by manufacturing cost, quality, regulatory compliance, and distribution networks, rather than intellectual property rights.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR API SUPPLIERS?

Suppliers of Amlodipine Besylate and Benazepril Hydrochloride APIs must navigate a complex web of international and national regulations to ensure product quality, safety, and market access.

Good Manufacturing Practices (GMP): This is the most critical regulatory requirement. Manufacturers must adhere to cGMP guidelines as set forth by regulatory bodies like the FDA (21 CFR Parts 210 & 211), EMA, and others. GMP covers all aspects of production, from raw material sourcing to finished product testing and distribution. Compliance is verified through regular inspections.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA's Type II DMF). A DMF contains detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies using the API reference the DMF in their drug product applications (e.g., ANDAs, New Drug Applications).
Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP): For APIs marketed in Europe, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that the API complies with the European Pharmacopoeia monograph. This can streamline the regulatory submission process in European Union member states.
ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines on quality, safety, efficacy, and multidisciplinary topics. Adherence to ICH guidelines (e.g., Q7 for GMP for APIs) is essential for global market access.
Impurity Profiling and Control: Regulatory bodies require rigorous control and reporting of impurities in APIs. Suppliers must identify, quantify, and control potential process-related impurities and degradation products to ensure the safety of the final drug product. Limits for known and unknown impurities are strictly defined.
Quality Agreements: Pharmaceutical companies that purchase APIs typically enter into quality agreements with their suppliers. These agreements detail responsibilities regarding quality control, change management, audits, and handling of deviations.
Supply Chain Security and Traceability: Regulations increasingly focus on ensuring the security and traceability of the pharmaceutical supply chain to prevent counterfeiting and diversion. This includes robust documentation and serialization requirements.
Environmental, Health, and Safety (EHS) Regulations: API manufacturing involves chemical processes that must comply with local and international EHS regulations regarding waste disposal, emissions, and worker safety.

Failure to comply with these regulations can lead to warning letters, import alerts, product recalls, and ultimately, loss of market access.

WHAT ARE THE KEY SUPPLY CHAIN RISKS FOR THESE APIS?

The global nature of API manufacturing for Amlodipine Besylate and Benazepril Hydrochloride exposes the supply chain to various risks.

Geopolitical and Economic Risks:

Geographic Concentration: A significant portion of API production for these drugs is concentrated in India and China. Geopolitical tensions, trade disputes, or political instability in these regions can disrupt supply.
Economic Sanctions and Trade Wars: Tariffs or sanctions imposed between major trading blocs could increase the cost of raw materials or finished APIs, or restrict market access.
Currency Fluctuations: Volatility in exchange rates can impact the cost of imported raw materials and the profitability of API exports.

Manufacturing and Quality Risks:

Single-Sourcing Dependency: Relying on a single supplier for a critical API can be highly risky. Any disruption at that supplier's facility (e.g., fire, equipment failure, labor strike, regulatory shutdown) can lead to stockouts.
Quality Control Failures: Despite stringent regulations, quality lapses can occur. FDA warning letters, import alerts, or product recalls due to GMP non-compliance at a supplier can halt production and supply.
Raw Material Shortages: The synthesis of complex APIs requires specific starting materials and intermediates. Shortages of these precursors, due to their own supply chain issues or production problems, can impact API availability.
Capacity Constraints: While the market is competitive, sudden surges in demand or the exit of smaller players can lead to temporary capacity constraints among remaining suppliers.

Regulatory and Compliance Risks:

Changes in Regulations: Evolving regulatory requirements, particularly concerning impurity limits or environmental standards, can necessitate costly changes in manufacturing processes.
Inspection Failures: Unexpected inspection failures by regulatory bodies can lead to production halts and delays in product release.
Intellectual Property Disputes: While the core patents have expired, disputes over process patents or trade secrets can arise, potentially impacting a supplier's ability to operate or sell their product.

Logistics and Transportation Risks:

Shipping Disruptions: Global shipping delays, port congestion, or increased freight costs can impact the timely delivery of APIs to formulation sites.
Natural Disasters: Earthquakes, floods, or pandemics can affect manufacturing facilities and transportation routes in key supply regions.

Cybersecurity Risks:

Data Breaches: Increasingly, API manufacturers are reliant on digital systems for production control and quality management. Cyberattacks could disrupt operations or compromise sensitive data.

To mitigate these risks, pharmaceutical companies often employ strategies such as multi-sourcing of APIs, rigorous supplier qualification and auditing, maintaining safety stock levels, and developing robust business continuity plans.

KEY TAKEAWAYS

The supply of Amlodipine Besylate and Benazepril Hydrochloride APIs is dominated by manufacturers in India and China.
Both drugs are genericized, with their primary patents having expired years ago, leading to a highly competitive API market driven by cost and quality.
API suppliers must adhere to stringent global regulatory standards, including cGMP, and maintain detailed Drug Master Files.
Key supply chain risks include geographic concentration of manufacturing, potential quality control failures, raw material availability, geopolitical instability, and logistical disruptions.
Diversification of suppliers and robust quality management systems are crucial for mitigating supply chain vulnerabilities.

FREQUENTLY ASKED QUESTIONS

What is the primary regulatory hurdle for new API suppliers entering the market for Amlodipine Besylate or Benazepril Hydrochloride? The primary hurdle is demonstrating consistent compliance with current Good Manufacturing Practices (cGMP) and successfully filing a comprehensive Drug Master File (DMF) that meets the stringent review requirements of regulatory agencies like the FDA or EMA.
How does the cost of raw materials influence the pricing of Amlodipine Besylate and Benazepril Hydrochloride APIs? The cost of specific precursor chemicals, reagents, and solvents used in the multi-step synthesis directly impacts the overall manufacturing cost of the API. Fluctuations in the prices of these raw materials, often influenced by global commodity markets and supply chain dynamics, are a significant factor in the final API pricing.
What are the typical quality control tests performed on Amlodipine Besylate and Benazepril Hydrochloride APIs before release? Typical quality control tests include assay (to determine potency), identification (e.g., via HPLC, IR spectroscopy), purity analysis (to quantify impurities by HPLC), residual solvent analysis (by GC), heavy metals testing, and physical property characterization (e.g., melting point, particle size distribution if critical). Stability studies are also conducted to establish shelf life.
In the event of a supply disruption from a primary API manufacturer, what strategies can pharmaceutical companies employ to ensure continuity of finished drug product manufacturing? Pharmaceutical companies typically maintain safety stock of critical APIs, qualify secondary or tertiary suppliers to enable rapid switching, and have robust business continuity plans in place. Establishing long-term contracts with multiple qualified suppliers can also mitigate risk.
Are there significant differences in the manufacturing complexity and required synthesis routes for Amlodipine Besylate versus Benazepril Hydrochloride APIs? Both APIs are produced through multi-step organic synthesis, each involving distinct chemical pathways and intermediates. While both are complex, the specific reagents, reaction conditions, purification techniques, and number of steps can vary significantly, influencing manufacturing efficiency, cost, and potential impurity profiles.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 & 211 – Current Good Manufacturing Practice For Finished Pharmaceuticals. U.S. Government Publishing Office. [2] European Medicines Agency. (n.d.). EudraLex Volume 4 – Good Manufacturing Practice (GMP). European Union. [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Council of Europe. [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Quality Guidelines. Retrieved from https://www.ich.org/page/quality-guidelines

Suppliers and packagers for generic pharmaceutical drug: AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE